Business
Axogen : J.P. Morgan 2026 Healthcare Conference
Axogen : J.P. Morgan 2026 Healthcare
About this update from Axogen, Inc.
Making Nerve Repair an Expected Standard of Care A commitment to restoring health, improving quality of life, and advancing peripheral nerve care for every patient. Michael Dale, President & CEO January 202 1 6 Our Mission To restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care. 3 Large and Underserved $5.6B US Nerve Care Opportunity More than 1.5 million peripheral nerve injuries a year require treatment in Axogen focus markets Extremities Market Breast Reconstruction Oral, Maxillofacial & Head & Neck Prostate Surgery $2.9B Every year patients suffer from 700,000 Traumatic Nerve Injuries and more than 370,000 Chronic nerve injuries . 1 $677M 1 of 8 women diagnosed with breast cancer. 80% of women experience pain, numbness or both after breast cancer surgery . 2 $1.2B Nerve damage caused by Oral Maxillofacial and H&N surgery is common and can result in loss of sensation and chronic pain. $754M 1 of 8 men diagnosed with prostate cancer. 25-90% experience Incontinence and Erectile Dysfunction (ED) Post robotic prostatectomy. 3,4 Nerve injuries have a significant impact on patient's quality of life… 4 Common Types and Causes of Peripheral Nerve Injury Neuroma Cut or Laceration Compression Stretching Trauma Trauma that leads to damaged nerves Severe Cuts, Falling Though Glass, Compression, Gunshot Wound, Blunt Trauma Surgery Nerves that have been cut, compressed or stretched during surgery Mastectomy, Laparoscopy, Tumor Resection, Wrist or Knee Arthroscopy, Hip or Knee Arthroplasty Amputation Stump pain associated with nerve damage has been reported in over 68% of amputees 5 Sensitivity to Touch, Residual Limb Pain, Burning Pain 5 The Axogen Nerve Repair Algorithm Connection Protection Termination 6 Avance ® is the First Approved Biologic Treatment for Repair of Nerve Discontinuities in adult and pediatric patients aged one month and older Preserves the delicate 3D macro and micro architecture of native nerve, which provides structural support for the regenerating axons Bioactive laminin necessary for supporting neurite growth & axonal regeneration Proprietary quality assays verify structural integrity & potency NATIVE NERVE 7 Our Key Market Development Opportunities Nerve Care is Not an Expected Standard of Care Care guidelines and standardized treatment algorithms are lagging and to be developed for certain care pathways Awareness of Treatment Options Low patient and surgeon awareness of treatment options Inefficient Patient Referral and Care Pathways Approximately 60% of nerve injuries go undiagnosed prior to patient discharge 6 Coverage & Payment 35% of commercial lives remain uncovered 1 8 2025-2028 Strategic Plan Priorities Growth CAGR 15 - 20% Markets Elective and planned procedure focus Prostate market development Commercial Expansion Commercial infrastructure and salesforce expansion Commercial Excellence Continuous business model and customer creation process optimization by market Standard of Care Level 1 clinical evidence generation for societal support, standard of care & coverage requirements Innovation Product development to drive better benefit versus risk profiles in nerve care 9 Uniquely Positioned to Lead in Nerve Repair Technology Expertise Access AVANCE ® (acellular nerve allograft-arwx) is the only FDA approved biologic nerve scaffold for treating peripheral nerve discontinuities Axoguard ® and Avive+ products for use across Axogen nerve repair algorithm 16 years of experience and 200,000+ patients treated 300+ clinical and scientific publications supporting our nerve repair algorithm A valued educational partner committed to clinical science and innovation Trusted partner to 6,500+ surgeons Established access in more than 2,700 hospitals and outpatient centers, supported by the largest direct sales channel 10 Attention : This is an excerpt of the original content. To continue reading it, access the original document here .